Código QR

Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features

MET exon 14 (METex14) skipping is the most reported MET mutation in non-small cell lung cancer (NSCLC) and has been confirmed to respond to MET tyrosine kinase inhibitors (TKI) in clinical trials. While MET TKI tepotinib was recently approved for METex14 skipping NSCLC in China, real-world evidence...

ver descrição completa

Na minha lista:
Principais autores: Yan Meng, Weiping Zhou, Chenping Li, Xiangjie Zhou, Xiao Li, Liang Li, Qiye Fu, Jue Huang, Yali Yue, Xuguang Shen, Lijing Yang, Meiqing Wang
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-07-01
Colecção:Frontiers in Oncology
Assuntos:
tepotinib
lung cancer
METex14
case series
MET TKI
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2024.1383964/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados